Citius Pharmaceuticals Stock Analysis

CTXR Stock  USD 0.82  0.02  2.50%   
Citius Pharmaceuticals is undervalued with Real Value of 1.9 and Target Price of 5.33. The main objective of Citius Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Citius Pharmaceuticals is worth, separate from its market price. There are two main types of Citius Pharmaceuticals' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect Citius Pharmaceuticals' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of Citius Pharmaceuticals' stock to identify patterns and trends that may indicate its future price movements.
The Citius Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Citius Pharmaceuticals is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Citius Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Citius Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.

Citius Stock Analysis Notes

About 17.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 1.5. Some equities with similar Price to Book (P/B) outperform the market in the long run. Citius Pharmaceuticals recorded a loss per share of 0.26. The entity last dividend was issued on the 9th of June 2017. The firm had 1:15 split on the 9th of June 2017. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. Citius Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 15 people. For more info on Citius Pharmaceuticals please contact Myron Holubiak at 908 967 6677 or go to https://citiuspharma.com.

Citius Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Citius Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Citius Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Citius Pharmaceuticals has some characteristics of a very speculative penny stock
Citius Pharmaceuticals had very high historical volatility over the last 90 days
Net Loss for the year was (32.54 M) with profit before overhead, payroll, taxes, and interest of 0.
Citius Pharmaceuticals currently holds about 48.04 M in cash with (29.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Citius Pharmaceuticals has a very weak financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Smith Robert Joseph of 75000 shares of Citius Pharmaceuticals at 0.69 subject to Rule 16b-3

Citius Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Citius Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Citius Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
9th of February 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of January 2025
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
30th of September 2023
Last Financial Announcement
View

Citius Largest EPS Surprises

Earnings surprises can significantly impact Citius Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2023-08-14
2023-06-30-0.05-0.06-0.0120 
2022-12-22
2022-09-30-0.04-0.05-0.0125 
2022-08-11
2022-06-30-0.05-0.06-0.0120 
View All Earnings Estimates

Citius Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Citius Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Citius Pharmaceuticals backward and forwards among themselves. Citius Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Citius Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Goldman Sachs Group Inc2023-12-31
185.1 K
Inspire Advisors, Llc2023-12-31
182.7 K
Bank Of America Corp2023-12-31
180.6 K
Barclays Plc2023-12-31
168.8 K
Key Bridge Compliance Llc2023-09-30
154.1 K
Rhumbline Advisers2023-12-31
150.1 K
Susquehanna International Group, Llp2023-12-31
141 K
Ubs Group Ag2023-12-31
137.5 K
Arkadios Wealth Advisors2023-12-31
100 K
Blackrock Inc2023-12-31
8.5 M
Vanguard Group Inc2023-12-31
6.9 M
Note, although Citius Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Citius Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 131.11 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Citius Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Citius Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Citius Profitablity

Citius Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Citius Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Citius Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Citius Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Citius Pharmaceuticals' profitability requires more research than a typical breakdown of Citius Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2024
Return On Capital Employed(0.43)(0.41)
Return On Assets(0.28)(0.30)
Return On Equity(0.41)(0.39)

Management Efficiency

Citius Pharmaceuticals has return on total asset (ROA) of (0.2321) % which means that it has lost $0.2321 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4097) %, meaning that it created substantial loss on money invested by shareholders. Citius Pharmaceuticals' management efficiency ratios could be used to measure how well Citius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/28/2024, Return On Capital Employed is likely to grow to -0.41. In addition to that, Return On Assets is likely to drop to -0.3. At this time, Citius Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 03/28/2024, Total Current Assets is likely to grow to about 41.5 M, while Other Assets are likely to drop slightly above 36 K.
Last ReportedProjected for 2024
Price Book Value Ratio 1.03  1.08 
Enterprise Value Multiple(1.91)(2.01)
Price Fair Value 1.03  1.08 
The analysis of Citius Pharmaceuticals' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Citius Pharmaceuticals' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Citius Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.44

Technical Drivers

As of the 28th of March, Citius Pharmaceuticals shows the Mean Deviation of 3.27, downside deviation of 3.61, and Risk Adjusted Performance of 0.0352. Citius Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We have analyzed and interpolated nineteen technical drivers for Citius Pharmaceuticals, which can be compared to its rivals. Please confirm Citius Pharmaceuticals variance and potential upside to decide if Citius Pharmaceuticals is priced correctly, providing market reflects its regular price of 0.82 per share. Given that Citius Pharmaceuticals is a hitting penny stock territory we recommend to closely look at its total risk alpha.

Citius Pharmaceuticals Price Movement Analysis

The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Citius Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Citius Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Citius Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Citius Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Citius Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Citius Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Citius Pharmaceuticals Predictive Daily Indicators

Citius Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Citius Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Citius Pharmaceuticals Forecast Models

Citius Pharmaceuticals' time-series forecasting models are one of many Citius Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Citius Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Citius Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Citius Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Citius shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Citius Pharmaceuticals. By using and applying Citius Stock analysis, traders can create a robust methodology for identifying Citius entry and exit points for their positions.
Last ReportedProjected for 2024
Pretax Profit Margin 0.00  0.00 
Operating Profit Margin 0.00  0.00 
Net Profit Margin 0.00  0.00 
Gross Profit Margin 0.00  0.00 

Current Citius Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Citius analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Citius analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
5.33Buy2Odds
Citius Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Citius analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Citius stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Citius Pharmaceuticals, talking to its executives and customers, or listening to Citius conference calls.
Citius Analyst Advice Details

Citius Stock Analysis Indicators

Citius Pharmaceuticals stock analysis indicators help investors evaluate how Citius Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Citius Pharmaceuticals shares will generate the highest return on investment. By understating and applying Citius Pharmaceuticals stock analysis, traders can identify Citius Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow41.7 M
Common Stock Shares Outstanding151.3 M
Total Stockholder Equity90.8 M
Tax Provision576 K
Property Plant And Equipment Net455.9 K
Cash And Short Term Investments26.5 M
Cash26.5 M
Accounts Payable2.9 M
Net Debt-26 M
50 Day M A0.719
Total Current Liabilities5.8 M
Other Operating Expenses36.7 M
Non Current Assets Total69.2 M
Forward Price Earnings1.2887
Non Currrent Assets Other45 M
Stock Based Compensation6.6 M
When determining whether Citius Pharmaceuticals is a strong investment it is important to analyze Citius Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Citius Pharmaceuticals' future performance. For an informed investment choice regarding Citius Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Citius Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest.
To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.
You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.

Complementary Tools for Citius Stock analysis

When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Is Citius Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Pharmaceuticals. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.26)
Return On Assets
(0.23)
Return On Equity
(0.41)
The market value of Citius Pharmaceuticals is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Citius Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Pharmaceuticals' market value can be influenced by many factors that don't directly affect Citius Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Citius Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.